The Scientific Advisory Board (SAB) of the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) program met in September to discuss the results of the HIV Prevention Trials Network (HPTN) 052 trial, which found that individuals with HIV infection who were given immediate antiretroviral therapy (ART) were 96 percent less likely to transmit the virus […]
The TB Alliance announced Tuesday that it has enlisted the help of the National Institute of Allergy and Infectious Diseases (NIAID) AIDS Clinical Trial Group (ACTG) to help complete testing of a potentially shorter tuberculosis treatment regimen utilizing an antibiotic not currently registered to treat TB – moxifloxacin.
Dr. Mean Chhi Vun, director of Cambodia’s National Center for HIV/AIDS, Dermatology and STDs (NCHADS), offered an exciting progress report to the TB/HIV Working Group of the Stop TB Partnership at their meeting last week in Beijing, including representatives from tuberculosis (TB) and HIV programs in China and elsewhere in the Pacific region…
Last week the World Health Organization (WHO) and the TB Alliance joined with pharmaceutical companies AstraZeneca, Bayer, Sanofi and Tibotec in an innovative agreement to share information about tuberculosis (TB) compounds in their drug pipelines and speed the development of new regimens, including the most promising multi-drug treatments, regardless of sponsor. Science Speaks sat down with Mel Spigelman, MD, president and chief executive officer of the TB Alliance, to discuss the new collaboration, which promising drug combinations are coming down the pipeline, and how their work is expediting the process.
The 17th Core Group Meeting of the TB/HIV Working Group kicked off in Beijing China with opening remarks from Dr. Yu Jingin, director of the Disease Control Bureau of the China Ministry of Health, and Dr. Wang You, director of the China Centers for Disease Control (CDC). Dr. Jingin informed the international audience that China […]